Exclusive Summary

• Originator patents have long expired, stripping away intellectual property barriers and allowing for rapid, risk-free global market entry via Distribution agreements.
• Driven by a global prevalence of over 40-50 million atrial fibrillation patients requiring life-long management, the 80mg standard starting dose guarantees massive and highly recurring market demand.
• Recognized on the WHO Essential Medicines List and heavily recommended by AHA/ESC guidelines, establishing undeniable clinical value as a cornerstone rhythm-control therapy.
• Leveraging China's robust API-FDF integrated manufacturing ecosystem, it offers compelling cost advantages and supply chain resilience to win local government tenders and secure lucrative distributor margins.